Achillion Pharmaceuticals, Inc. (ACHN) Shares Sold by Artal Group S.A.

Artal Group S.A. cut its stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 25.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 750,000 shares of the biopharmaceutical company’s stock after selling 250,000 shares during the quarter. Artal Group S.A.’s holdings in Achillion Pharmaceuticals were worth $2,160,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. grew its stake in shares of Achillion Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock worth $2,100,000 after acquiring an additional 2,850 shares during the period. Wells Fargo & Company MN grew its stake in shares of Achillion Pharmaceuticals by 1.8% in the second quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock worth $1,009,000 after acquiring an additional 3,827 shares during the period. Voya Investment Management LLC grew its stake in shares of Achillion Pharmaceuticals by 13.7% in the second quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 6,730 shares during the period. UBS Asset Management Americas Inc. grew its stake in shares of Achillion Pharmaceuticals by 18.6% in the second quarter. UBS Asset Management Americas Inc. now owns 63,669 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 10,000 shares during the period. Finally, Nationwide Fund Advisors grew its stake in shares of Achillion Pharmaceuticals by 15.2% in the second quarter. Nationwide Fund Advisors now owns 93,443 shares of the biopharmaceutical company’s stock worth $429,000 after acquiring an additional 12,303 shares during the period. Hedge funds and other institutional investors own 76.81% of the company’s stock.

Achillion Pharmaceuticals, Inc. (ACHN) opened at $3.20 on Friday. The stock has a market cap of $459.83, a P/E ratio of -6.53 and a beta of 1.32. Achillion Pharmaceuticals, Inc. has a 1-year low of $2.58 and a 1-year high of $5.66.

A number of equities analysts recently issued reports on ACHN shares. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Monday, November 6th. BidaskClub downgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, January 13th. Leerink Swann reissued a “buy” rating and issued a $5.00 price objective on shares of Achillion Pharmaceuticals in a report on Monday, December 11th. Finally, B. Riley started coverage on shares of Achillion Pharmaceuticals in a report on Thursday, February 8th. They issued a “neutral” rating and a $3.50 price objective on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $4.89.

In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $2.75, for a total value of $50,510,201.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 7.24% of the company’s stock.

WARNING: “Achillion Pharmaceuticals, Inc. (ACHN) Shares Sold by Artal Group S.A.” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/02/18/achillion-pharmaceuticals-inc-achn-shares-sold-by-artal-group-s-a.html.

Achillion Pharmaceuticals Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply